PDL BioPharma Inc. announced the completion of the previously announced spinoff of its femtosecond laser system business LENSAR. Beginning Oct. 2, LENSAR shares began “regular way” trading on the Nasdaq composite exchange. LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of preexisting or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist surgeons in obtaining better outcomes, efficiency, and reproducibility through advanced imaging and procedure planning.